Crohn Disease Clinical Trial
Official title:
The Influence of the Bmgim Music Therapy Method in the Reduction of Stress in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis): Quantitative and Qualitative Study
Verified date | June 2019 |
Source | University of Valencia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Inflammatory bowel disease (IBD) is a term that defines a chronic disease characterized by
inflammation of the intestine. It includes ulcerative colitis (UC) and Crohn's disease (CD).
The objective of the study was to administer a treatment based on a group adaptation of the
BMGIM in patients with inflammatory bowel disease (IBD) and assess its impact on state of
mind, quality of life, anxiety, depression, immunocompetence as a marker of well-being, and
levels of acute and chronic stress.
To achieve the objectives a quasi-experimental, quantitative, qualitative, analytical, and
prospective study was performed. 41 patients with IBD divided into a test group (24
patients), who received 8 sessions over 8 weeks, and a control group (17 patients). A saliva
sample was taken from each patient before and after each session to determine cortisol levels
(acute stress) and IgA (immunocompetence) using ELISA. A series of questionnaires were
completed as follows: HADS (perceived anxiety), MOOD (state of mind), and CCVEII (quality of
life). Similarly, a hair sample was taken before the first and after the last session to
determine the cumulative cortisol level (chronic stress) using ELISA.
Status | Completed |
Enrollment | 51 |
Est. completion date | January 31, 2017 |
Est. primary completion date | June 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 69 Years |
Eligibility |
Inclusion Criteria: - Over 18 years old, - Diagnosed IBD (EC or UC) in the remission phase, - They did not receive treatment with corticosteroids at least in the two months prior to the start of the study, - They did not receive any extra pharmacological treatment, - Attend the collaborating hospital center with the study, in this case, the University General Hospital of Valencia, - Attend the schedule and schedule established for the study, - Accept the conditions of participation in the study indicated in the signed informed consent prior to the start of the study - * Do not take corticosteroids during the 8 weeks between the pre-test and the post-test, - * Perform the pre-test before starting session 1 (in case of experimental group) or appointment 1 (in case of control group); and then the retest at the end of session 8 (in the case of an experimental group) or appointment with nursing after 8 weeks (in the case of a control group). - * In the case of the patients belonging to the experimental group, who at the end of the 8 weeks of treatment would have attended at least 6 of the 8 sessions established (and that, obligatorily, 2 of them were 1 and 8, where the shots were taken) sample and completed the questionnaires). Exclusion Criteria: The patients who were excluded from this study were those who did not meet the requirements indicated in the inclusion criteria, or who showed aversion or rejection to this type of therapy. |
Country | Name | City | State |
---|---|---|---|
Spain | Universitat de València | Valencia |
Lead Sponsor | Collaborator |
---|---|
University of Valencia | Hospital General Universitario de Valencia, Universidad Católica de Valencia San Vicente Mártir |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in biological markers in saliva samples using enzyme-linked immunosorbent biological markers assay (ELISA) (PRE and POST Measures). | Quantifying change in biological markers in saliva samples using enzyme-linked immunosorbent assay (ELISA). (IgA level & Salivary Cortisol) comparing pre and post intervention | Baseline up to 8 weeks of treatment | |
Primary | Change in biological markers in hair using enzyme-linked immunosorbent assay (ELISA).(PRE and POST Measures). | Quantifying change in biological markers in hair (Cortisol Hair) comparing pre and post intervention | Baseline up to 8 weeks of treatment | |
Primary | Change in Hospital Anxiety and Depression Scale (HADS) (PRE and POST Measures) | 14 items. 7 items for Anxiety and 7 for Depression. The score for the items is evaluated on a Likert scale ranging from 0 to 3 points, where 0 represents never or almost never, 1 a little or from time to time, 2 somewhat less than before or not as intense, and 3 maximum or almost always. Lastly, it is worth mentioning that these scales are interpreted based on the sum of each dimension, with 21 as the maximum, both for depression and for anxiety. Higher values represent a worse outcome. Observing change comparing pre and post intervention | Baseline up to 8 weeks of treatment | |
Primary | Change in Short-form Questionnaire on Quality of Life in IBD (CCVEII-9) (PRE and POST Measures) | 9 items grouped in a single dimension The final score is expressed on a scale of 0 to 100 points, such that a lower score corresponds to a lower quality of life and vice versa. Observing change comparing pre and post intervention | Baseline up to 8 weeks of treatment | |
Primary | Change in the MOOD questionnaire (PRE and POST Measures). | The scale evaluates the frequency of the different states of mind (happiness, anger, sadness, and fear) based on 20 items (4 dimensions of 5 items each). The responses for the items were measured using a 3-point Likert scale (1=never, 2=sometimes, 3=often). Each dimension range from 1 to 3. There is not a total of all dimensions together. a lower score corresponds to high level fo that mood (lower values= a betwer outcome on anger, sadness, and fear and worst outcome on hapiness). Observing change comparing pre and post intervention | Baseline up to 8 weeks of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Recruiting |
NCT05169593 -
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
|
Phase 4 | |
Recruiting |
NCT06116604 -
Early Bowel Resection for Terminal Ileal Crohn's Disease
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT05627128 -
A Culturally Tailored Dietary Intervention to Treat Crohn's Disease
|
N/A | |
Recruiting |
NCT05294107 -
Intestinal Organoids
|
N/A | |
Withdrawn |
NCT04349449 -
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
|
||
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT03058679 -
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
|
N/A | |
Completed |
NCT02871635 -
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
|
Phase 3 | |
Recruiting |
NCT04266600 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease
|
N/A | |
Recruiting |
NCT04539665 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.
|
N/A | |
Recruiting |
NCT03913572 -
Treatment of Perianal Disease Using Adipose-derived Stem Cells
|
||
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Terminated |
NCT04102111 -
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
|
Phase 2 | |
Recruiting |
NCT04997733 -
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
|
Phase 3 | |
Recruiting |
NCT05906576 -
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
|
Phase 4 | |
Not yet recruiting |
NCT04502303 -
18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease
|
Phase 2 | |
Not yet recruiting |
NCT04398836 -
Preoperative Nutrition for Crohn's Disease Patients
|
Phase 3 |